** Brokerage Leerink Partners raises PT on biotech firm Blueprint Medicines Corp BPMC.O to $98 from $89; maintains "market perform" rating
** New PT represents a 5.1% downside to the stock's last close
** BPMC is testing BLU-808 for the treatment of mast cell disorders, a condition where the immune system overreacts, causing symptoms such as hives, itching, and swelling
** Brokerage says "BLU-808 data supports advancement into proof-of-concept trials in allergic and inflammatory diseases"
** Brokerage notes BLU-808's reductions in serum tryptase, an enzyme released by mast cells in the blood, are "encouraging", given they appear relatively in line with competitor Celldex Therapeutics' CLDX.O barzolvolimab
** Brokerage says the biomarker response at low doses could help BLU-808 manage side effects, despite concerns about hair color changes
** BPMC fell 4.2% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。